New triple therapy aims to shrink stomach tumors in First-Line trial
NCT ID NCT07502027
First seen Apr 17, 2026 · Last updated May 04, 2026 · Updated 3 times
Summary
This study tests a new treatment for people with advanced stomach or gastroesophageal junction cancer that has not spread too far and is HER2-negative. The treatment combines two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy (SOX) after a special type of radiation therapy. The goal is to see if this combination can shrink tumors and control the disease. The study plans to enroll 55 adults aged 18-75 who have not had prior treatment for advanced disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.